Neuroscience · us
How Does APOE4 Impair Neuronal “Insulation”? Study Finds Experimental Clues to Myelin Repair
APOE4, which is associated with Alzheimer’s disease risk, may cause myelin-producing cells to accumulate fat while being unable to use it properly. Researchers improved myelin formation in human cell models and mice by modulating Wnt signaling, but key questions remain before this could become a treatment for patients.
Smooth transmission of neural signals depends not only on neurons themselves but also on the myelin sheath surrounding their axons. This lipid-rich layer of “insulation” is produced by oligodendrocytes. When these cells contain fat but cannot use it properly, gaps may emerge in the support system for neural networks. A new study links this problem to APOE4, a major genetic risk variant for Alzheimer’s disease.
A team led by Li-Huei Tsai of MIT’s Picower Institute and first author Leyla Akay reported in a study published in *Cell Stem Cell* on October 15 that oligodendrocytes carrying APOE4 showed suppressed Wnt signaling, lipid droplet accumulation, and insufficient myelin formation. Restoring this signaling pathway improved myelin formation in both human cell models and mice, offering a therapeutic direction for further investigation.
To identify the causes of fat accumulation, the team conducted a genome-wide CRISPR screen in oligodendrocytes derived from human induced pluripotent stem cells, systematically testing which genes altered lipid droplet accumulation. Another line of evidence came from ATAC sequencing: comparing cell cultures and human postmortem brain tissue samples, the researchers found that chromatin associated with genes that promote Wnt signaling was less accessible to the transcriptional machinery in APOE4 samples than in APOE3 samples. Both approaches pointed to dysregulated Wnt signaling.
Further analysis showed lower expression of β-catenin in APOE4 oligodendrocytes and higher levels of GSK3β, which inhibits this signaling pathway. This moved the research focus from why cells accumulate fat to a molecular step that could be experimentally tested: could reducing GSK3β activity improve both lipid handling and myelin formation?
According to the paper’s abstract listed by the Broad Institute, inhibiting GSK3β through either genetic manipulation or drugs reduced lipid droplets in APOE4 oligodendrocytes; myelin formation also increased in three-dimensional brain organoids. MIT further explained that organoid experiments using the research compound CHIR99021 also showed increased growth of neuronal axons. These findings extended beyond a reduction in intracellular fat to a model comprising both these cells and neurons.
The animal experiments used mice carrying both APOE4 and the PS19 tau pathology model. After drug treatment, the mice had fewer lipid droplets in the hippocampus and greater myelin formation than untreated controls. Reporting on the same study, Europa Press’s Infosalus likewise identified the restoration of myelin in human cells and mice as a main finding of the work.
However, improvements in myelin markers cannot yet be equated with restored memory or a slowing of Alzheimer’s disease progression. This study provides preclinical mechanistic evidence and proof of concept; it does not demonstrate that patients will benefit. Progress toward treatment will still require clarification of the safety of long-term modulation of this signaling pathway, suitable methods of administration, and whether changes in myelin can translate into measurable improvements in cognition and daily functioning.